Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2025.08.071 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Maya Granot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray…. Hauptthemen laut MEDLINE: Infliximab, Adalimumab, Drug Substitution, Crohn Disease. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Israel Science Foundation, Tel Aviv University, European Research Council.
Abstract (Originalsprache)
BACKGROUND AND AIMS: The development of antibodies to infliximab (ATI) is a major challenge in pediatric inflammatory bowel disease (IBD). This real-world study aimed to identify predictors of ATI, evaluate strategies to overcome ATI, and compare the durability of continuing infliximab (IFX) versus switching to adalimumab (ADA) after ATI development. METHODS: We retrospectively analyzed 194 pediatric IBD patients treated with IFX from 2010 to 2024. ATI titers were measured uniformly before each infusion. Demographic data, disease characteristics, ATI titers, infusion reactions, management strategies, and treatment durability were collected and analyzed. RESULTS: ATI developed in 52 of 194 patients (26.8 %), more frequently in Crohn's disease (31.2 %) than ulcerative colitis (16.1 %, p < 0.01), and was associated with female gender (57.7 % vs. 39.4 %, p = 0.03) and younger age at diagnosis. High-titer ATI (≥8 mcg/ml-eq) correlated with infusion reactions (56.5 % vs. 3.5 %, p < 0.001). ATI was managed with dose/interval adjustment (61.9 %), immunomodulator addition (16.7 %), or both (21.4 %). IFX continuation was successful in 71.4 %, especially in low-titer ATI (92.0 % vs. 41.2 %, p < 0.001). IFX durability after ATI was significantly longer (median 94 months) than ADA after switching (47 months, p < 0.01). CONCLUSIONS: About 27 % of pediatric IBD patients developed ATI to IFX. Personalized management can restore IFX efficacy and provides superior long-term outcomes compared to switching to ADA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv…
- The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.
Förderung
- Israel Science Foundation
- Tel Aviv University
- European Research Council
- Leona M and Harry B Helmsley Charitable Trust
Zitieren
APA
Granot, M., Nachum, N., Krauthammer, A., Berger, T. D., Heiman, S., Yavzori, M., Picard, O., Ben-Horin, S., Weiss, B., & Haberman, Y. (2025). Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.08.071
Vancouver
Granot M, Nachum N, Krauthammer A, Berger TD, Heiman S, Yavzori M, et al. Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.08.071
BibTeX
@article{Granot2025,
author = {Granot, Maya and Nachum, Nurit and Krauthammer, Alexander and Berger, Tal David and Heiman, Sophia and Yavzori, Miri and Picard, Orit and Ben-Horin, Shomron and Weiss, Batia and Haberman, Yael},
title = {Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2025.08.071}
}
EUVIMED